Reynalda deJesus
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Nitric Oxide and Endothelin Effects, Microbial Natural Products and Biosynthesis, Diabetes Treatment and Management, Renin-Angiotensin System Studies
Most-Cited Works
- → Dicarboxylic Acid Dipeptide Neutral Endopeptidase Inhibitors(1995)81 cited
- → Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines(1991)44 cited
- → Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors(2001)32 cited
- → Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists(2009)22 cited
- → The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes(2012)18 cited
- → Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor(2017)10 cited
- → Structure Guided Discovery of Novel Pan Metallo-β-Lactamase Inhibitors with Improved Gram-Negative Bacterial Cell Penetration(2024)6 cited
- → Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic(2021)5 cited
- → Quantitation of wall teichoic acid in Staphylococcus aureus by direct measurement of monomeric units using LC-MS/MS(2016)2 cited
- → Dipeptide sulfonamides as endothelin ETA/ETB receptor antagonists(2002)1 cited